Bank of New York Mellon Corp Purchases Shares of 11,642 Syros Pharmaceuticals, Inc. (SYRS)
Bank of New York Mellon Corp purchased a new stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,642 shares of the company’s stock, valued at approximately $185,000.
Separately, Wells Fargo & Company MN bought a new stake in Syros Pharmaceuticals during the first quarter worth approximately $225,000. Hedge funds and other institutional investors own 49.45% of the company’s stock.
Shares of Syros Pharmaceuticals, Inc. (NASDAQ SYRS) traded up 0.90% on Friday, hitting $21.24. 3,841 shares of the stock traded hands. Syros Pharmaceuticals, Inc. has a one year low of $8.47 and a one year high of $24.38. The company’s market cap is $496.85 million. The stock has a 50 day moving average of $19.31 and a 200 day moving average of $15.32.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Equities analysts anticipate that Syros Pharmaceuticals, Inc. will post ($2.09) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Purchases Shares of 11,642 Syros Pharmaceuticals, Inc. (SYRS)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/bank-of-new-york-mellon-corp-purchases-shares-of-11642-syros-pharmaceuticals-inc-syrs.html.
A number of research firms have commented on SYRS. Wedbush reaffirmed an “outperform” rating and issued a $22.84 target price (down previously from $25.00) on shares of Syros Pharmaceuticals in a research report on Thursday. JMP Securities downgraded shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $20.81.
In related news, insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the completion of the transaction, the insider now owns 2,500 shares in the company, valued at $58,975. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at approximately $273,125. The disclosure for this sale can be found here. Insiders sold 18,282 shares of company stock valued at $404,599 in the last quarter.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS).
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.